DENALI THERAPEUTICS INC (DNLI)
US24823R1059 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 127.11M | 218.00M | 293.50M | 507.10M | 79.40M | |||
| Marketable Securities | 907.40M | 1.12B | 571.90M | 962.60M | 335.90M | |||
| Receivables | N/A | 0.00 | 1.20M | 5.70M | N/A | |||
| Other Current Assets | 29.63M | 36.10M | 30.60M | 20.30M | 14.70M | |||
| Total Current Assets | 1.06B | 1.37B | 897.20M | 1.50B | 430.00M | |||
| Non-Current Assets | ||||||||
| PPE Net | 71.64M | 74.50M | 69.60M | 73.50M | 80.70M | |||
| Investments And Advances | N/A | 0.00 | 425.40M | 32.70M | 39.90M | |||
| Other Non-Current Assets | 18.14M | 13.40M | 11.90M | 2.50M | 2.70M | |||
| Total Non-Current Assets | 89.78M | 87.90M | 507.00M | 108.60M | 123.20M | |||
| TOTAL ASSETS | 1.15B | 1.46B | 1.40B | 1.60B | 553.20M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 68.50M | 66.70M | 53.20M | 47.10M | 24.00M | |||
| Accounts Payable | 9.48M | 2.80M | 4.80M | 1.10M | 2.60M | |||
| Other Current Liabilities | 0.00 | 294.40M | 320.30M | 23.50M | 18.70M | |||
| Total Current Liabilities | 77.98M | 363.90M | 378.20M | 71.70M | 45.30M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 44.98M | 53.90M | 63.60M | 382.10M | 113.00M | |||
| Total Non-Current Liabilities | 44.98M | 53.90M | 63.70M | 382.00M | 113.00M | |||
| TOTAL LIABILITIES | 122.96M | 417.80M | 441.90M | 453.70M | 158.30M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -1.12B | -971.00M | -645.00M | -354.40M | -425.60M | |||
| Additional Paid In Capital | 2.14B | 2.02B | 1.61B | 1.50B | 818.80M | |||
| Common Shares | 1.71M | 1.70M | 1.50M | 1.50M | 1.30M | |||
| Other Shareholders' Equity | 643.00K | -6.90M | -2.50M | -200.00K | 400.00K | |||
| Shares Outstanding | 138.39M | 136.00M | 122.30M | 120.50M | 96.20M | |||
| Tangible Book Value per Share | 7.45 | 7.66 | 7.87 | 9.55 | 4.11 | |||
| Total Shareholders' Equity | 1.03B | 1.04B | 962.30M | 1.15B | 394.90M | |||
| TOTAL LIABILITIES AND EQUITY | 1.15B | 1.46B | 1.40B | 1.60B | 553.20M | |||
| Statistics | ||||||||
| Current Ratio | 13.65 | 3.77 | 2.37 | 20.86 | 9.49 | |||
| Return On Assets (ROA) | -12.59% | -22.33% | -20.70% | 4.43% | -35.72% | |||
| Return On Equity (ROE) | -14.09% | -31.27% | -30.20% | 6.18% | -50.04% | |||
| Return On Invested Capital (ROIC) | N/A | N/A | N/A | 3.23% | N/A | |||
| Return On Invested Capital Ex Cash (ROICexc) | N/A | N/A | N/A | 78.75% | N/A | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | N/A | N/A | N/A | 78.75% | N/A | |||
All data in USD